[{"id":"b4b092ce-836a-4461-a13c-fdf80069c46d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02298946","created_at":"2021-01-18T10:50:38.153Z","updated_at":"2024-07-02T16:37:02.551Z","phase":"Phase 1","brief_title":"AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02298946","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • AMP-224 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 11/21/2014","start_date":" 11/21/2014","primary_txt":" Primary completion: 07/13/2016","primary_completion_date":" 07/13/2016","study_txt":" Completion: 03/07/2017","study_completion_date":" 03/07/2017","last_update_posted":"2019-02-22"},{"id":"b30f8265-8840-48e7-afb9-3860161e54a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352884","created_at":"2021-01-18T05:31:54.500Z","updated_at":"2025-02-25T13:16:49.424Z","phase":"Phase 1","brief_title":"Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer","source_id_and_acronym":"NCT01352884","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMP-224"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2016-09-05"}]